Back to discover
Disease

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Late-stage therapeutic developmentEmerging research
MeSHLeukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Publications
6
Clinical trials
2
Related proteins
2020
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q3 2030.
Upcoming Milestones
Clinical Milestones1View
Results expected 1
Activity timeline1

Clinical trials

5 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
6
All trials
1
Active
2
Late-stage
5
Completed
Recently completed

Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)

Phase 2 · Completed · University Hospital, Bordeaux

A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate (Glivec®) Plasmatic Through Level in Patients Newly Diagnosed With Chronic Phase Chronic Myelogenous Leukaemia (CP-CML).

Phase 2 · Completed · Versailles Hospital

A Phase 3 Multinational, Multi-center, Open-Label, Randomized Study of the Efficacy of Radotinib Versus Imatinib in Newly Diagnosed Ph+ CML Patients in Early Chronic Phase

Phase 3 · Completed · Il-Yang Pharm. Co., Ltd.

An Extension to a Phase II Study to Determine the Efficacy and Safety of STI571 in Patients With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha

Phase 2 · Completed · Novartis Pharmaceuticals

Treatment of CML Patients With Imatinib and Hydroxyurea

Phase 1/2 · Completed · University of Leipzig

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
19902020
Major themes1
  • Philadelphia Chromosome1
Leading journals2
  • Leukemia1
  • Science (New York, N.Y.)1
Leading researchers8
  • Apperley JF1
  • Baccarani M1
  • Baltimore D1
  • Cervantes F1
  • Clark RE1
  • Cortes JE1
  • Daley GQ1
  • Deininger MW1
Affiliations (unnormalised)6
  • Almazov National Research Centre1
  • Amsterdam University Medical Center1
  • Centre Hospitalier de Versailles1
  • Centre Hospitalier Universitaire de Poitiers1
  • Centre Léon Bérard1
  • Department Clinical Medicine and Surgery1

Disease biology

2 matches

Key proteins & gene products studied in this disease. Number shows shared papers.

Fusion Proteins, bcr-abl2Janus Kinases2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.

Identifiers
MeSHLeukemia, Myelogenous, Chronic, BCR-ABL Positive
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.